On Thursday, Bruker Corporation(NASDAQ:BRKR)’s shares declined -0.55% to $18.00.
Bruker Corporation (BRKR) declared a major version 3.0 expansion of the proven Mycobacteria Library for research use only on the MALDI Biotyper microbial mass spectrometry system.
The new Mycobacteria Library 3.0 now comprises 149 different species for comprehensive species coverage, enabling significantly improved rapid and accurate identification of almost all described mycobacteria species. Intra-species diversity is covered by hundreds of analyzed strains. Twenty-four laboratories from nine countries from all over the world offered well-characterized clinical mycobacteria strains, concluding an already comprehensive set of isolates from strain collections. A recently published research study has shown that out of 1,045 mycobacteria samples, 94% could be identified on the species level with high confidence, and another 4.5% could be identified with lower confidence [1], using Mycobacteria Library 3.0.
Bruker Corporation, together with its auxiliaries, designs, manufactures, sells, and services proprietary life science and materials research systems, and associated products worldwide. It operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies.
Buckle Inc(NYSE:BKE)’s shares dropped -2.68% to $40.61.
The Buckle, Inc. (BKE) declared that net income for the fiscal quarter ended August 1, 2015 was $23.5 million, or $0.49 per share ($0.49 per share on a diluted basis).
Net sales for the 13-week fiscal quarter ended August 1, 2015 raised 0.1 percent to $236.1 million from net sales of $235.7 million for the preceding year 13-week fiscal quarter ended August 2, 2014. Comparable store net sales for the 13-week period ended August 1, 2015 reduced 1.7 percent from comparable store net sales for the preceding year 13-week period ended August 2, 2014. Online sales raised 17.4 percent to $20.1 million for the 13-week period ended August 1, 2015, contrast to net sales of $17.1 million for the 13-week period ended August 2, 2014.
Net sales were $507.4 million for both the 26-week fiscal period ended August 1, 2015 and the 26-week fiscal period ended August 2, 2014. Comparable store net sales for the 26-week period ended August 1, 2015 reduced 2.0 percent from comparable store net sales for the preceding year 26-week period ended August 2, 2014. Online sales raised 14.9 percent to $44.3 million for the 26-week period ended August 1, 2015, contrast to net sales of $38.6 million for the 26-week period ended August 2, 2014.
The Buckle, Inc. operates as a retailer of casual apparel, footwear, and accessories for young men and women in the United States. It markets a selection of brand name casual apparel, counting denims, other casual bottoms, tops, sportswear, outerwear, accessories, and footwear. The company operates stores under the Buckle and The Buckle names. The Buckle, Inc. also sells its products through its Website, buckle.com. As of March 24, 2015, it operated 462 retail stores in 44 states.
At the end of Thursday’s trade, Ocata Therapeutics Inc(NASDAQ:OCAT)‘s shares dipped -6.39% to $4.54.
Ocata Therapeutics, Inc. (OCAT), a leader in the field of Regenerative Ophthalmology™, recently declared that it has reached a secured term loan facility of up to $10 million with Silicon Valley Bank. Ocata received initial funding of $6 million and has a conditional option to receive an additional $4 million upon the successful completion of certain clinical and corporate milestones. Ocata intends to use the proceeds for general corporate purposes counting the initiation of the Phase 2 dry age-related macular degeneration (AMD) and pivotal Stargardt’s macular degeneration (SMD) clinical studies and the advancement of its promising pre-clinical programs.
Ocata Therapeutics, Inc., a clinical stage biotechnology company, develops and commercializes regenerative ophthalmology therapeutics in the United States. The company is conducting various clinical trials for treating Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, in addition to pre-clinical trials for the treatment of other ocular disorders; and has pre-clinical stage assets in disease areas outside the field of ophthalmology, counting autoimmune, inflammatory, and wound healing-related disorders. Its intellectual property portfolio comprises pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms.
MiMedx Group Inc(NASDAQ:MDXG), ended its Thursday’s trading session with 0.94% gain, and closed at $9.67.
MiMedx Group, Inc. (MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare, declared recently that its latest peer-reviewed scientific study, “Dehydrated Human Amnion/Chorion Membrane Regulates Stem Cell Activity In Vitro,” was electronically published in the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
The electronic publication of the peer-reviewed article is now accessible in the Wiley Online Library and can be found at http://onlinelibrary.wiley.com/doi/10.1002/jbm.b.33478/abstract. The paper was authored by Michelle Massee; Kathryn Chinn; Jennifer Lei; Jeremy J. Lim, PhD; Conan S. Young, PhD; and Thomas J. Koob, PhD. The hard copy publication is predictable to follow in a future issue of the Journal of Biomedical Materials Research: Part B – Applied Biomaterials.
MiMedx Group, Inc. develops, processes, and markets patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. Its biomaterial platform technologies are AmnioFix, EpiFix, and CollaFix. The company’s AmnioFix and EpiFix are tissue technologies processed from human amniotic membrane derived from donated placentas.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
